SenoRx' breast brachytherapy tool:
This article was originally published in Clinica
The US FDA has given SenoRx 510(k) clearance to market its Multi-Lumen Radiation Balloon Applicator for providing brachytherapy to the surgical margins following lumpectomy for breast cancer. The device uses vacuum to remove excess fluid and to adhere closely to often irregularly shaped lumpectomy cavities in order to deliver precise radiation dosing through multiple seed lumens. "Certain patients who are presently candidates for balloon therapy are currently excluded because of the location of the lesion relative to their breast size," claimed Lloyd Malchow, the Aliso Viejo, California firm's president and CEO. "Our multi-lumen approach offers a solution to this problem."
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.